Ed Silverman is the founding editor of Pharmalot and a prize-winning journalist who has covered the pharmaceutical industry for the past 15 years for The Star-Ledger of New Jersey, The Pink Sheet and, currently, as an editor-at-large for Med Ad News and R&D Directions.
Laura is the Generalist at TickerTags.
She runs an independent finance blog called TickerChicks with Daria Woods.
She holds a B.B.A., Finance from Southern Methodist University.
Previous work includes being an investment opportunity researcher at a biofuel company in London.
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.
I am an American born Indian that graduated with a degree in Biology and a minor in chemistry and business administration and a Masters in Physiology. My senior year, after realizing I did not want to go to medical school I began to research and learn about the healthcare vertical as it applied to the stock market. I am interested in bridging the gap between business and healthcare which is the essence of what the stock market can help us do. I look to constantly gain more experience, understanding, and drive entrepreneurship in the healthcare space as well as those it effects.
Interested in technology and financial markets. Undergrad in engineering, MS in Comp Sci and an MBA in finance. Building tools for individual investors to make more informed decisions about the stocks and mutual funds they choose.
Identify businesses that have long-term sustainable growth opportunities and are trading at a good value.
Capital Markets consultant and active investor in the emerging life science space. Tenured futures trader. Able to provide access to a pool of investors and traders throughout the US and UK. ProActive Capital, a capital markets advisory firm that makes direct investments and provides advisory services into public and private life science companies. Areas of focus include; capital introduction, shareholder management, communications and investor outreach.